Related Experiment Video
Updated: Aug 4, 2026

Treatment with Vancomycin Loaded Calcium Sulphate and Autogenous Bone in an Improved Rabbit Model of Bone Infection
Published on: March 14, 2019
Oral vancomycin-induced rash: case report and review of the literature
J M McCullough1, D G Dielman, D Peery
1College of Pharmacy, University of Michigan, Ann Arbor 48109.
Abstract:
Disseminated rash and pruritus are described in an 82-year-old woman with chronic renal failure following administration of oral vancomycin hydrochloride 125 mg q6h for the treatment of Clostridium difficile colitis. Renal function was estimated to be 0.27 mL/s based on a serum creatinine of 177 mumol/L. After eight days of therapy, she developed a slightly raised maculopapular rash on her legs and torso, which spread to her abdomen and arms with continued treatment. Vancomycin was discontinued and the patient was treated symptomatically. The rash cleared and did not recur. Rechallenge with vancomycin was not initiated. No other changes in medications or initiations of new medications occurred during the time of treatment with vancomycin. The patient denied any previous immunologically mediated reactions to medications. Maculopapular rash is rare secondary to vancomycin administration, particularly after oral administration. Although clinically significant serum concentrations can be obtained in patients treated with oral vancomycin who have concomitant C. difficile colitis and renal failure, there has not been a clear correlation between these concentrations and any reported adverse sequelae. This case supports the possible occurrence of a true allergic reaction secondary to low-dose oral vancomycin administration.
Insights
A rare maculopapular rash occurred in an elderly patient with renal failure treated with oral vancomycin for Clostridium difficile colitis. This case suggests a possible allergic reaction to low-dose oral vancomycin.
Area of Science:
- Pharmacology
- Dermatology
- Nephrology
Background:
- Vancomycin is a critical antibiotic for treating Clostridium difficile colitis.
- Oral vancomycin is generally considered safe with minimal systemic absorption.
- Patients with chronic renal failure may have altered drug metabolism and excretion.
Observation:
- An 82-year-old female with chronic renal failure developed a disseminated maculopapular rash and pruritus.
- The rash appeared after eight days of oral vancomycin hydrochloride (125 mg q6h) for C. difficile colitis.
- No other new medications were introduced, and the patient had no prior drug allergies.
Findings:
- The maculopapular rash spread despite continued oral vancomycin therapy.
- Discontinuation of vancomycin led to the resolution of the rash without recurrence.
- This event is rare, especially with oral vancomycin administration.
Implications:
- This case highlights a potential, albeit rare, allergic reaction to low-dose oral vancomycin.
- Clinicians should consider vancomycin hypersensitivity in patients with renal impairment presenting with rash.
- Further investigation may be warranted to understand the correlation between serum vancomycin concentrations and adverse events in this population.
More Related Videos
07:50A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
Published on: September 20, 2018
06:02Cationic Nanoemulsion-Encapsulated Retinoic Acid as an Adjuvant to Promote OVA-Specific Systemic and Mucosal Responses
Published on: February 23, 2024
Related Concept Videos
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Endocarditis I: Introduction
Staphylococcal Skin Infections
Candidiasis
Clinical Significance of Antibiotic Resistance
Peptic Ulcer Disease III: Clinical Manifestations and Complications